Skip to main content
SpringerLink
Log in

Ramipril gives high HOPE to patients with cardiovascular disease

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

Results from a landmark study have shown that the ACE inhibitor ramipril prevents major cardiovascular events in patients with a history of vascular disease or diabetes mellitus. The Heart Outcomes Prevention Evaluation (HOPE) trial showed that ramipril reduces the risk of cardiovascular mortality, stroke or myocardial infarction (MI) by 22% in this patient group. Results were presented at the 21st Congress of the European Society of Cardiology [ Barcelona, Spain; August-September 1999 ], where HOPE investigators said that the study represents one of the greatest discoveries in heart disease treatment worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Carmen Innes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Innes, C. Ramipril gives high HOPE to patients with cardiovascular disease. Inpharma Wkly. 1206, 15–16 (1999). https://doi.org/10.2165/00128413-199912060-00032

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199912060-00032

Keywords

Search

Navigation